SciELO - Scientific Electronic Library Online

 
vol.21 número3Principales causas relacionadas con el abandono del tratamiento ortodóncico por escolares y adultos jóvenes según tipos de aparatos utilizadosValor de la vena digital para el diagnóstico tradicional y pronóstico de las diarreas en una lactante índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


MEDISAN

versión On-line ISSN 1029-3019

Resumen

CLAPE LAFFITA, Oneyda et al. Implementation of immunotherapeutical products in cancer clinical trials in Santiago de Cuba. MEDISAN [online]. 2017, vol.21, n.3, pp.313-319. ISSN 1029-3019.

A retrospective descriptive study on the presentation of clinical trials was carried out during 23 years in Santiago de Cuba, with the objective of describing the implementation of 3 immunotherapeutical products (CIMAher-Nimotuzumab, CIMAvax-EGF and Vaxira-Racotumomab) for the treatment of patients with cancer in hospitals and polyclinics from the province. The final reports of each clinical trial and the available information of the promoter center were reviewed from 1992 to 2015. Twenty protocols of clinical trials were implemented by 500 investigators of 25 specialties distributed in 4 hospitals of the province and 4 primary health care areas, where 2 clinical trials in patients with lung cancer were carried out. It was concluded that the implementation of these immunotherapeutical products contributed to the health registration of them, enriching the therapeutic arsenal for the treatment of patients with cancer in Santiago de Cuba, with a high social impact

Palabras clave : immunotherapeutical products; CIMAher-Nimotuzumab; CIMAvax-EGF and Vaxira-Racotumomab; clinical trial.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons